CHEMBL2093866 Target Snapshot

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Estrogen receptor shows approved-linked disease relevance led by menopause. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q92731. Start with menopause, then reuse UniProt Q92731 as the stable protein anchor across project notes and exports.

Review focus

Review-ready target frame

Start with menopause, then reuse UniProt Q92731 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 9 linked drugs

Open source guide

Disease program

menopause

Estrogen receptor shows approved-linked disease relevance led by menopause. 5 more disease programs remain visible in the same review block. 9 linked drugs remain visible in the same block.

Start review with menopause because it currently carries approved-linked support. Linked drugs include BAZEDOXIFENE ACETATE, ESTETROL, ESTRIOL, ESTROGENS, CONJUGATED. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy

Approved-linked Open Targets-ready proxy 9 linked drugs

Open disease block

Protein anchor

Estrogen receptor beta

Review this target as Estrogen receptor, mapped to UniProt Q92731. ChEMBL maps the protein component as Estrogen receptor beta. Sequence length is 530 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt Q92731 Protein 530 aa

Open protein block

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Estrogen receptor as ChEMBL target CHEMBL2093866, mapped to UniProt Q92731. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Estrogen receptor

PROTEIN FAMILY · Homo sapiens

As of 2026-09-14

ChEMBL target ID

CHEMBL2093866

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-14

www.ebi.ac.uk

UniProt accession

Q92731

Estrogen receptor beta

UniProt accession via ChEMBL component mapping As of 2026-09-14

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-14

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Start here when your first question is whether Estrogen receptor is the right protein anchor across sources, using UniProt Q92731 as the stable mapping.

Jump to Protein Context

Need disease fit before discussing compounds?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why menopause is currently framed as approved-linked support. It currently carries 9 linked drugs in the same disease frame.

Jump to Disease Context

Need a meeting-ready explanation of why this target matters?

Evidence Card

Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card

Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name	Estrogen receptor
Target Type	PROTEIN FAMILY
Organism	Homo sapiens
UniProt	Q92731

ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label	Estrogen receptor beta
UniProt Accession	Q92731
Component Type	Protein
Sequence Length	530 aa

Estrogen receptor beta

Source · UniProt accession via ChEMBL component mapping Freshness · Sep 14, 2026, 1:58 PM KST As of · Sep 14, 2026

UniProt Context ↗

Review Cue

How to read this target

Review this target as Estrogen receptor, mapped to UniProt Q92731. ChEMBL maps the protein component as Estrogen receptor beta. Sequence length is 530 aa.

Mapped IDQ92731

Review nameEstrogen receptor

OrganismHomo sapiens

Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Estrogen receptor shows approved-linked disease relevance led by menopause. 5 more disease programs remain visible in the same review block.

Approved-linked Approved

menopause

9 linked drugs · 9 direct · 9 efficacy

Linked drugBAZEDOXIFENE ACETATE

Linked drugESTETROL

Linked drugESTRIOL

Linked drugESTROGENS, CONJUGATED

Approved-linked Approved

breast cancer

7 linked drugs · 7 direct · 7 efficacy

Linked drugAFIMOXIFENE

Linked drugARZOXIFENE

Linked drugESTETROL

Linked drugESTROGENS, CONJUGATED

Approved-linked Approved

Atrophy

5 linked drugs · 5 direct · 5 efficacy

Linked drugESTROGENS, CONJUGATED

Linked drugESTROGENS, CONJUGATED SYNTHETIC A

Linked drugESTROGENS, ESTERIFIED

Linked drugOSPEMIFENE

Approved-linked Approved

breast neoplasm

5 linked drugs · 5 direct · 5 efficacy

Linked drugARZOXIFENE

Linked drugESTETROL

Linked drugESTROGENS, CONJUGATED

Linked drugLASOFOXIFENE

Approved-linked Approved

osteoporosis

5 linked drugs · 5 direct · 5 efficacy

Linked drugARZOXIFENE

Linked drugBAZEDOXIFENE ACETATE

Linked drugESTROGENS, CONJUGATED

Linked drugLASOFOXIFENE

Approved-linked Approved

postmenopausal osteoporosis

4 linked drugs · 4 direct · 4 efficacy

Linked drugARZOXIFENE

Linked drugBAZEDOXIFENE ACETATE

Linked drugESTROGENS, CONJUGATED

Linked drugLASOFOXIFENE TARTRATE

Source · ChEMBL drug mechanism + indication proxy Freshness · Sep 14, 2026, 1:58 PM KST As of · Sep 14, 2026

ChEMBL target record ↗

Review Cue

How to read disease relevance

Start review with menopause because it currently carries approved-linked support. Linked drugs include BAZEDOXIFENE ACETATE, ESTETROL, ESTRIOL, ESTROGENS, CONJUGATED. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemenopause

Strongest levelApproved-linked

Block modeOpen Targets-ready proxy

Clinical Profile

Clinical Phase Distribution

15

Approved

2

Phase III

5

Phase II

Assay Mix

Activity Type Distribution

IC50559.0

KI98.0

EC5069.0

KD9.0

Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL ID	pChEMBL	Type	Value (nM)	Phase
CHEMBL135	11.0	EC50	0.01	Approved
CHEMBL135	11.0	IC50	0.01	Approved
CHEMBL68055	10.82	Ki	0.015	Clinical
CHEMBL308234	10.8	Ki	0.016	Preclinical
CHEMBL291808	10.55	Ki	0.028	Preclinical
CHEMBL537254	10.3	IC50	0.05	Preclinical
CHEMBL181248	10.15	IC50	0.07	Preclinical
CHEMBL328190	10.0	IC50	0.1	Approved
CHEMBL135	9.95	Ki	0.113	Approved
CHEMBL411	9.9	Ki	0.126	Approved

Distribution

pChEMBL Value Distribution

14

5.0

43

5.5

71

6.0

62

6.5

60

7.0

45

7.5

66

8.0

64

8.5

67

9.0

25

9.5

pChEMBL

Approved Drugs

LASOFOXIFENE

CHEMBL328190

Approved 2009

Properties Compare Identifier

FULVESTRANT

CHEMBL1358

Approved 2002

Properties Compare Identifier

RALOXIFENE

CHEMBL81

Approved 1997

Properties Compare Identifier

RALOXIFENE HYDROCHLORIDE

CHEMBL1116

Approved 1997

Properties Compare Identifier

TAMOXIFEN

CHEMBL83

Approved 1977

Properties Compare Identifier

ESTRADIOL

CHEMBL135

Approved 1975

Properties Compare Identifier

DIETHYLSTILBESTROL

CHEMBL411

Approved 1973

Properties Compare Identifier

MEDROXYPROGESTERONE ACETATE

CHEMBL717

Approved 1959

Properties Compare Identifier

Assay Landscape

363

Total Assays

303

Tested Compounds

3

Assay Types

Binding — 211 assays, 108 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
protein format	164	69	7.9
cell-based format	42	33	6.8
assay format	3	2	5.5
tissue-based format	2	4	9.5

Functional — 148 assays, 303 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
cell-based format	91	246	7.7
assay format	46	45	6.4
organism-based format	11	12	7.4

ADME — 4 assays, 0 compounds

BAO Format	Assays	Compounds	Avg pChEMBL
cell-based format	4	0	—

CHEMBL2093866 Target Snapshot

Research home keeps recent targets

Switch target

Frame the target before identity details

Cross-source identity

Start with the right source

Basic Information

Next Actions

UniProt Target Context

How to read this target

Disease Relevance & Evidence Level

How to read disease relevance

Clinical Phase Distribution

Activity Type Distribution

Top Inhibitors (by pChEMBL)

pChEMBL Value Distribution

Approved Drugs

Assay Landscape

Confidence Score Distribution